nach oben

Erschienen in:

01.02.2020 | Original Article

The role of socioeconomic status in the susceptibility to develop systemic lupus erythematosus in Mexican patients

verfasst von: Norma Alicia Salgado-Galicia, Susana Hernández-Doño, Daniela Ruiz-Gómez, Juan Jakez-Ocampo, Joaquín Zúñiga, Gilberto Vargas-Alarcón, Víctor Acuña, María Teresa Hernández, José Eduardo Márquez-García, Maricela García-Lechuga, Luis Llorente, Guadalupe Lima, Carlos Pineda, Neng Yu, Edmond Yunis, Julio Granados

Erschienen in: Clinical Rheumatology | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disorder for which Major Histocompatibility Complex (MHC) genes are well-identified as risk factors. SLE patients have different phenotypes or clinical presentations, which vary among Mexicans. This variation could be explained by ethnicity and admixture. Since socioeconomic status probably limits and change the patterns of migration, this factor could favor inbreeding and homogamy in some geographic areas. Consequently, it could alter or restrict the possibilities of admixture too. Therefore, the socioeconomic status may also have implications in the susceptibility and the clinical heterogeneity of SLE in Mexican patients.

Methods

One hundred twenty-three SLE patients and 234 healthy individuals with Mexican admixed ancestry were recruited. HLA alleles were analyzed using the HLA typing method based on Sequence-based typing (SBT).

Results

As expected, it was found an increased frequency of the HLA-DRB1*03:01 allele in all socioeconomic groups when compared with healthy individuals. The susceptibility allele found in the low-income SLE patients was HLA-DRB1*04:05 whereas, the susceptibility alleles for the high-income SLE patients were HLA-DRB1*07:01 (pC = 0.03, OR = 2.0) and HLA-DRB1*11:04 (pC = 0.0004, OR = 5.1). Additionally, the frequencies of two protective alleles HLA-DRB1*14:06 (pC = 0.01, OR = 0.28) and HLA-DRB1*16:02 (pC = 0.04, OR = 0.22) were found diminished. These findings correlate with the admixture differences between low-income and high-income SLE patients. The clinical manifestations showed a different distribution between both groups. Arthritis and neurological disorder were prevalent in low-income SLE patients, while the hematological disorder was prevalent in high-income SLE patients.

Conclusions

These findings suggest that HLA class II DRB1 genes contribute to the susceptibility and protection to develop SLE differently depending on socioeconomic status. Due to this, the clinical manifestations vary among patients and it could be related to different admixture charge.

Key Point

• HLA class II DRB1 genes contribute to the susceptibility and protection to develop SLE differently depending on socioeconomic status.

Ghodke-Puranik Y, Niewold TB (2015) Immunogenetics of systemic lupus erythematosus: a comprehensive review. J Autoimmun 64:125–136. https://doi.org/10.1016/j.jaut.2015.08.004 CrossRefPubMedPubMedCentral

Valencia-Flores M, Reséndiz MC, Santiago V, Castaño V, Granados J, Camarena A et al (2010) Sleep, fatigue, depression, and pain in Mexican women with systemic lupus erythematosus: an exploratory study. Hisp Heal Care Int 8(4):217–226. https://doi.org/10.1891/1540-4153.8.4.217 CrossRef

Carter EE, Barr SG, Clarke AE (2016) The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 12(10):605–620. https://doi.org/10.1038/nrrheum.2016.137 CrossRefPubMed

Tsokos GC, Lo MS, Reis PC, Sullivan KE (2016) New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 12(12):716–730. https://doi.org/10.1038/nrrheum.2016.186 CrossRefPubMed

Walid W, Noor Eldeen E, Essam HM, Adel A, Khaled DH, Hamad AA et al (2014) Relation between HLA typing and clinical presentations in systemic lupus erythematosus patients in Al-Qassim region, Saudi Arabia. Int J Health Sci (Qassim) 8(2):159–165CrossRef

Vasconcelos C, Carvalho C, Pereira C, Bettencourt A, Costa PP, Barbosa P et al (2009) HLA in Portuguese systemic lupus erythematosus patients and their relation to clinical features. Ann N Y Acad Sci 580:575–580. https://doi.org/10.1111/j.1749-6632.2009.04873.x CrossRef

Granados J, Zúñiga J, Acuña-Alonzo V, Rosetti F, Vargas-Alarcón G (2006) Influencia de alelos y haplotipos del complejo principal de histocompatibilidad en la susceptibilidad a lupus eritematoso generalizado en la población mexicana. Gac Med Mex 142(3):195–199PubMed

Furukawa H, Kawasaki A, Oka S, Ito I, Shimada K, Sugii S, Hashimoto A, Komiya A, Fukui N, Kondo Y, Ito S, Hayashi T, Matsumoto I, Kusaoi M, Amano H, Nagai T, Hirohata S, Setoguchi K, Kono H, Okamoto A, Chiba N, Suematsu E, Katayama M, Migita K, Suda A, Ohno S, Hashimoto H, Takasaki Y, Sumida T, Nagaoka S, Tsuchiya N, Tohma S (2014) Human leukocyte antigens and systemic lupus erythematosus: a protective role for the HLA-DR6 alleles DRB1*13:02 and *14:03. PLoS One 9(2):1–7. https://doi.org/10.1371/journal.pone.0087792 CrossRef

Kim K, Bang SY, Lee HS, Okada Y, Han B, Saw WY, Teo YY, Bae SC (2014) The HLA-DRβ1 amino acid positions 11-13-26 explain the majority of SLE-MHC associations. Nat Commun 5:5902. https://doi.org/10.1038/ncomms6902 CrossRefPubMed

10.

Ceccarelli F, Perricone C, Borgiani P, Ciccacci C, Rufini S, Cipriano E et al (2015) Genetic factors in systemic lupus erythematosus: contribution to disease phenotype. J Immunol Res 2015:1–11. https://doi.org/10.1155/2015/745647 CrossRef

11.

Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, Villa AR, Abadi I, Caeiro F, Alvarellos A, Alarcón-Segovia D, Grupo Latinoamericano de Estudio del Lupus (2004) The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine. 83(1):1–17. https://doi.org/10.1097/01.md.0000104742.42401.e2 CrossRefPubMed

12.

Moreno-Estrada A, Gignoux CR, Fernandez-Lopez JC, Zakharia F, Sikora M, Contreras AV et al (2014) The genetics of Mexico recapitulates Native American substructure and affects biomedical traits. Science 344(6189):1280–1285. https://doi.org/10.1126/science.1251688 CrossRefPubMedPubMedCentral

13.

Mizuno F, Gojobori J, Wang L, Onishi K, Sugiyama S, Granados J, Gomez-Trejo C, Acuña-Alonzo V, Ueda S (2014) Complete mitogenome analysis of indigenous populations in Mexico: its relevance for the origin of Mesoamericans. J Hum Genet 59(7):359–367. https://doi.org/10.1038/jhg.2014.35 CrossRefPubMed

14.

Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725–1734. https://doi.org/10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y CrossRef

15.

Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcón-Segovia D (1992) Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 19(10):1551–1558PubMed

16.

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640CrossRef

17.

Zúñiga J, Yu N, Barquera R, Alosco S, Ohashi M, Lebedeva T, Acuña-Alonzo V, Yunis M, Granados-Montiel J, Cruz-Lagunas A, Vargas-Alarcón G, Rodríguez-Reyna TS, Fernandez-Viña M, Granados J, Yunis EJ (2013) HLA class I and class II conserved extended haplotypes and their fragments or blocks in Mexicans: implications for the study of genetic diversity in admixed populations. PLoS One 8(9). https://doi.org/10.1371/journal.pone.0074442

18.

Robinson J, Malik A, Parham P, Bodmer JG, Marsh SGE (2001) IMGT/HLA database-a sequence database for the human major histocompatibility complex. Nucleic Acids Res 29(1):210–213

19.

Lebedeva TV, Mastromarino SA, Lee E, Ohashi M, Alosco SM, Yu N (2011) Resolution of HLA class I sequence-based typing ambiguities by group-specific sequencing primers. Tissue Antigens 77(3):247–250. https://doi.org/10.1111/j.1399-0039.2010.01616.x CrossRefPubMed

20.

Wang J (2003) Maximum-likelihood estimation of admixture proportions from genetic data. Genetics. 164:747–765PubMedPubMedCentral

21.

Rodriguez-sanchez J (2002) Molecular analysis of HLA-DRB1 polymorphism in north-east Spain. Eur J Immunogenet 29:75–77. https://doi.org/10.1046/j.0960-7420.2001.00293.x CrossRefPubMed

22.

Paximadis M, Mathebula TY, Gentle NL, Vardas E, Colvin M, Gray CM, Tiemessen CT, Puren A (2012) Human leukocyte antigen class I (A,B,C) and II (DRB1) diversity in the black and Caucasian South African population. Hum Immunol 73(1):80–92. https://doi.org/10.1016/j.humimm.2011.10.013 CrossRefPubMed

23.

Arnaiz-villena A, Vargas-alarco G, Areces C, Enrı M, Abd-el-fatah-khalil S, Ferna M et al (2014) Mixtec Mexican Amerindians : an HLA alleles study for America peopling, pharmacogenomics, and transplantation. Immunol Investig 43(8):738–755. https://doi.org/10.3109/08820139.2014.926369 CrossRef

24.

García-Ortíz J, Sandoval-Ramírez L, Rangel-Villalobos H, Maldonado-Torres H, Cox S, García-Sepúlveda C et al (2006) High-resolution molecular characterization of the HLA class I and class II in the Tarahumara Amerindian population. Tissue Antigens 68(5):135–146. https://doi.org/10.1111/j.1399-0039.2006.00636.x CrossRefPubMed

25.

Ikeda N, Kojima H, Nishikawa M, Hayashi K, Futagami T, Tsujino T, Kusunoki Y, Fujii N, Suegami S, Miyazaki Y, Middleton D, Tanaka H, Saji H (2015) Determination of HLA-A, -C, -B, -DRB1 allele and haplotype frequency in Japanese population based on family study. Tissue Antigens 85:252–259. https://doi.org/10.1111/tan.12536 CrossRefPubMedPubMedCentral

26.

Gutierrez-Arcelus M, Rich SS, Raychaudhuri S (2016) Autoimmune diseases connecting risk alleles with molecular traits of the immune system. Nat Rev Genet 17(3):160–174. https://doi.org/10.1038/nrg.2015.33 CrossRefPubMedPubMedCentral

27.

Repeinertsen JL, Klippel JH, Jonhson AH, Steinberg AD, Decker JL, Mann DL (1978) B-lymphocyte alloantigens associated with systemic lupus erythematous. N Engl J Med 299(10). https://doi.org/10.1056/NEJM197809072991004

28.

Vargas-Alarcón G, Salgado N, Granados J, Gómez-Casado E, Martinez-Laso J, Alcocer-Varela J, Arnaiz-Villena A, Alarcón-Segovia D (2001) Class II allele and haplotype frequencies in Mexican systemic lupus erythematosus patients: the relevance of considering homologous chromosomes in determining susceptibility. Hum Immunol 62(8):814–820. https://doi.org/10.1016/j.humimm.2004.09.008 CrossRefPubMed

29.

Bekker-Mendez C, Yamamoto-Furusho JK, Vargas-Alarcon G, Ize-Ludlow D, Alcocer-Varela J, Granados J (1998) Haplotype distribution of class II MHC genes in Mexican patients with systemic lupus erythematosus. Scand J Rheumatol 27(5):373–376CrossRef

30.

Granados J, Vargas-Alarcón G, Andrade F, Melin-Aldana et al (1996) The role of HLA-DR alleles and complotypes through the ethnic barrier in systemic lupus erythematosus in Mexicans. Lupus. 5:184–189. https://doi.org/10.1177/096120339600500304 CrossRefPubMed

31.

Penaranda-Parada E, Quintana G, Yunis JJ, Mantilla R, Rojas W, Panqueva U et al (2015) Clinical, serologic, and immunogenetic characterization (HLA-DRB1) of late-onset lupus erythematosus in a Colombian population. Lupus. 24(12):1293–1299. https://doi.org/10.1177/0961203315588576 CrossRefPubMed

32.

Graham RR, Ortmann W, Rodine P, Espe K, Langefeld C, Lange E, Williams A, Beck S, Kyogoku C, Moser K, Gaffney P, Gregersen PK, Criswell LA, Harley JB, Behrens TW (2007) Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur J Hum Genet 15:823–830CrossRef

33.

Hashimoto H, Nishimura Y, Dong RP, Kimura A, Sasazuki T, Vamanakal K et al (1994) HLA antigens in Japanese patients with systemic lupus erythematosus. Rheumatology. 23(4):191–196

34.

Suggs MJL, Majithia V, Lewis RE, Cruse JM (2011) HLA DRB1*15:03 allelic haplotype predominance and associated immunodysregulation in systemic lupus erythematosus. Exp Mol Pathol. 91:548–562. https://doi.org/10.1016/j.yexmp.2011.03.006 CrossRefPubMed

35.

Niu Z, Zhang P, Tong Y (2015) Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int J Rheum Dis 18(1):17–28. https://doi.org/10.1111/1756-185X.12528 CrossRefPubMed

36.

Granados J, Vargas-Alarcón G, Drenkard C, Andrade F, Melín-Aldana H, Alcocer-Varela J, Alarcón-Segovia D (1997) Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA-DR7 in Mexican patients with systemic lupus erythematosus (SLE). Lupus. 6(1):57–62 http://www.ncbi.nlm.nih.gov/pubmed/9116720 CrossRef

37.

Trabace S, Nicotra M, Cappellacci S, Morellini M, Muttinelli C, Anna M et al (1991) HLA-DR and DQ antigens and anticardiolipin antibodies in women with recurrent spontaneous abortions. Am J Reprod Immunol 26:147–149CrossRef

38.

Panzer S, Pabinger I, Gschwandtner ME, Mayr WR, Hutter D (1997) Lupus anticoagulants : strong association with the major histocompatibility complex class II and platelet antibodies. Br J Haematol 98:342–345CrossRef

39.

Camps MT, Cuadrado MJ, Ocón P, et al (1995) Association between HLA class II antigens and primary antiphospholipid syndrome from the south of Spain. Lupus 4(1):51–55. https://doi.org/10.1177/096120339500400111

40.

González-Galarza FF, Takeshita LYC, Santos EJM, Kempson F, Thomaz Maia MH, Soares da Silva AL, Teles e Silva AL, Ghattaoraya GS, Alfirevic A, Jones A and Derek M (2015). Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Research. 43: 784–788, https://doi.org/10.1093/nar/gku1166. Allele Frequencies in Worldwide populations [Internet]. [Revised on April 2019] http://allelefrequencies.net/hla6006a.asp?hla_locus_type=Classical&hla_locus=DRB1&hla

Titel: The role of socioeconomic status in the susceptibility to develop systemic lupus erythematosus in Mexican patients
verfasst von: Norma Alicia Salgado-Galicia
Susana Hernández-Doño
Daniela Ruiz-Gómez
Juan Jakez-Ocampo
Joaquín Zúñiga
Gilberto Vargas-Alarcón
Víctor Acuña
María Teresa Hernández
José Eduardo Márquez-García
Maricela García-Lechuga
Luis Llorente
Guadalupe Lima
Carlos Pineda
Neng Yu
Edmond Yunis
Julio Granados
Publikationsdatum: 01.02.2020
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 7/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-04928-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The role of socioeconomic status in the susceptibility to develop systemic lupus erythematosus in Mexican patients

Abstract

Introduction

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

Are patients with rheumatologic diseases on chronic immunosuppressive therapy at lower risk of developing severe symptoms when infected with COVID-19?

Correction to: A systematic review of internet-based information for individuals with Raynaud’s phenomenon and patients with systemic sclerosis

Serum adipokine levels in patients with sarcoidosis

Prevalence of anti-DFS70 autoantibodies in a Latin American cohort of patients with systemic lupus erythematosus and without autoimmune diseases

TNF inhibitor treating osseous sarcoidosis and dactylitis: case and literature review

Correction to: Serum substance P: an indicator of disease activity and subclinical inflammation in rheumatoid arthritis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin